Biotechnology

Nature Cell's JointStem Has Been Designated as a Regenerative Medicine Advanced Therapy (RMAT) by the U.S. FDA

October 25, 2024 11:00 AM

LOS ANGELES, CA / ACCESSWIRE / October 25, 2024 / On October 23rd, Nature Cell Co., Ltd. proudly announced the receipt of RMAT designation for "JointStem," an innovative treatment for severe degenerative arthritis, from the U.S. FDA. The RMAT initiative by the U.S. FDA is designed to accelerate the development and approval of groundbreaking regenerative drugs that tackle critical medical needs, a revision made under the 21st Century Cures Act in...

Read more

Tharimmune Announces Upcoming Conference Presentations

October 25, 2024 8:00 AM

BRIDGEWATER, NJ / ACCESSWIRE / October 25, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces that management will be participating in two upcoming conferences. Nir Barak, M.D., Chief Medical Advisor, will present new results from the Company's Phase 1 trial of TH104 in a poster titled "P1780:...

Read more

English Edition of 'Stem Cells: The Secret of Reverse- Aging' by Dr. Jeong Chan Ra Now Available

October 24, 2024 12:45 PM

‘Stem Cells: The Secret of Reverse- Aging' by Dr. Jeong Chan Ra, founder of Nature Cell and director of Biostar Stem Cell Research Institute has been expertly translated into English in the United States to ensure that readers worldwide can access it through Amazon. It distills 20 years of the author's groundbreaking research and 15 years of practical application. Initially published in Korea on December 25, 2023, the book swiftly achieved sales...

Read more

MelliCell Awarded SEED Grant with Mass General Brigham to Propel Innovation in Diabetes and Obesity

October 24, 2024 10:00 AM

MelliCell Inc., a biotech company pioneering adipocyte therapies for chronic disease, with the support of Mass General Brigham, one of the nation's leading biomedical research organizations with several Harvard Medical School teaching hospitals, is proud to announce a prestigious award from the National Institutes of Health - National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK) SEED Fund. This grant, part of the Small...

Read more

Qr8 Health Cognition Suite Now Available on Epic Vendor Services Platform

October 24, 2024 9:00 AM

Qr8 Health, a leading provider of digital solutions for dementia and other neurological diseases, today announced that its flagship product, Qr8 Cognition SuiteTM, is now available via Epic Vendor Services-one of the world's most widely adopted electronic medical record (EMR) platforms. This new integration method builds on Qr8 Health's strong track record of successful EMR implementations across the US, Canada, and Europe, further enhancing the...

Read more

Alligator Bioscience AB Reports Financial Results for the First 9 Months of 2024 and for Q3 2024 and Provides a Business Update

October 24, 2024 2:20 AM

Alligator Bioscience (STO:ATORX) Recruitment completed of 450 µg/kg back-fill cohort in the mitazalimab OPTIMIZE-1 study in pancreatic cancer Positive interim Phase 1 data evaluating ALG.APV-527 monotherapy in multiple solid tumor types presented at ESMO Congress 2024 Lund, Sweden - Alligator Bioscience (Nasdaq Stockholm: ATORX) "We have made excellent progress over the last few months with preparations for our lead asset mitazalimab's Phase 3...

Read more

SpeeDx Appoints Jeremy Stackawitz as Chief Executive Officer to Drive Global Expansion of Its Molecular Diagnostics Solutions

October 23, 2024 5:00 PM

SYDNEY, AUSTRALIA / ACCESSWIRE / October 23, 2024 / SpeeDx, a leading innovator in molecular diagnostic solutions, today announced the appointment of Jeremy Stackawitz as Chief Executive Officer. With more than 25 years of leadership experience in the life sciences and diagnostics sectors, Stackawitz will focus on accelerating SpeeDx's commercialization, partnering and regulatory activities across key markets, including the United States. Jeremy...

Read more

TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

October 23, 2024 8:30 AM

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that TuHURA recently participated at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC. As part of the event, Dr. James Bianco, President and Chief Executive Officer of TuHURA participated in the Precision and...

Read more

TuHURA Biosciences (NASDAQ:HURA) to Present at the Virtual Investor "New to the Street" Event

October 22, 2024 9:00 AM

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that it will present at the Virtual Investor New to the Street Event on Wednesday, October 30, 2024 at 4:00 PM ET. As part of the event, Dr. Jim Bianco, President and Chief Executive Officer of TuHURA will provide a corporate overview...

Read more

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

October 22, 2024 8:45 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024, in Houston, Texas and virtually. Details of the presentation are as...

Read more

Biovica signs agreement with UK biotech company

October 22, 2024 2:20 AM

UPPSALA, SE / ACCESSWIRE / October 22, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in blood-based cancer monitoring, has signed a Master Service Agreement (MSA) for TKa testing with a UK-based pharma biotech company. Under this agreement, Biovica will deliver TKa testing services using its DiviTum® TKa assay and expertise in interpreting TKa measurement dynamics to support drug development and optimize...

Read more

Prolocor Announces Publication of Confirmatory Results From Multicenter 800 Patient Study in the Journal of the American College of Cardiology (JACC)

October 21, 2024 11:00 AM

Greater than 2-fold predictive value (p=0.001) for heart attack, stroke, and death Significant unmet need in balancing the risks and benefits of antithrombotic treatment in patients with acute coronary syndrome (ACS) Supports trend in individualized antiplatelet therapy PHILADELPHIA, PA / ACCESSWIRE / October 21, 2024 / Prolocor, Inc., a healthcare startup developing the innovative diagnostic Prolocor pFCG® test that identifies patients at...

Read more

TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics

October 17, 2024 4:35 PM

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy today announced the completion of its previously announced merger with Kintara Therapeutics, Inc. (now TuHURA Biosciences, Inc.). The combined company will operate under the name "TuHURA Biosciences, Inc." and will focus on advancing TuHURA's innate...

Read more

Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform

October 17, 2024 8:45 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced it has entered into a Materials Transfer Agreement with Tokyo Medical University to advance the development of its systemic DNase program. Under the terms of the agreement, Professor Takuro Nakamura of the Department of...

Read more

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1

October 17, 2024 8:30 AM

- Company Expands Phase 2 trial to Canada - POTOMAC, MD / ACCESSWIRE / October 17, 2024 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced enrollment of patients at the Baycrest Academy for Research and Education in Toronto, Ontario, Canada, as part of the Company's ongoing Phase 2 trial investigating IGC-AD1 as a treatment for agitation in Alzheimer's dementia. Agitation affects between 40-80% of Alzheimer's...

Read more

Athos Announces Positive Topline Phase 1 Data for its AI-Generated, Novel, Oral G9A Inhibitor ATH-063, Demonstrating Selective Expansion and Activation of Potent Anti-Inflammatory Regulatory T Cells

October 16, 2024 9:00 AM

LOS ANGELES, CA / ACCESSWIRE / October 16, 2024 / Athos Therapeutics, Inc. ("Athos"), a clinical stage biotechnology company pioneering the development of precision small molecule therapeutics for patients with immune-mediated diseases, today announced topline results for the company's Phase 1 clinical trial of ATH-063, an investigational oral small molecule G9A inhibitor and the company's lead asset in development for the treatment of...

Read more

Moolec Has Received USDA Approval for the First Genetically Modified Pea in History

October 16, 2024 6:00 AM

LUXEMBOURG / ACCESSWIRE / October 16, 2024 / Moolec Science SA (NASDAQ:MLEC) ("the Company"), a leader in Molecular Farming technology, announced today that the U.S. Department of Agriculture's ("USDA") Animal and Plant Health Inspection Service ("APHIS") has completed its Regulatory Status Review ("RSR") for the Company's genetically engineered ("GE") peas which produce iron through bovine meat proteins. This is the third regulatory clearance...

Read more

Seraxis Announces FDA IND Allowance for Clinical Study of SR-02 Replacement Islets for Type 1 Diabetes

October 15, 2024 8:00 AM

A Phase I/II Clinical Study to assess safety, potency and durability of SR-02 implanted to the abdominal omentum of patients with difficult-to-control T1D GERMANTOWN, MD / ACCESSWIRE / October 15, 2024 / Seraxis Inc., a clinical-stage regenerative medicine company, has received the FDA's allowance of an Investigational New Drug (IND) application for a Phase I/II clinical study of its novel islet replacement therapy SR-02. SR-02 is the first...

Read more

GB Sciences Signs Licensing Deal With EndoPure Life Sciences for 5% Gross Sales Royalty & Sponsorship of First-in-Human Trial for Their Cannabinoid-Based Parkinson’s Drug

October 15, 2024 7:00 AM

As a part of their Exclusive Licensing Deal, EndoPure Life Sciences will finance and sponsor first-in-human clinical trials, which help to advance GB Sciences' cannabinoid-based products globally. LAS VEGAS, NV / ACCESSWIRE / October 15, 2024 / GB Sciences, Inc. (OTCQB:GBLX), a leading data-driven, plant-inspired biopharmaceutical development company, has signed an exclusive licensing deal with EndoPure Life Sciences, LLC, a company with...

Read more

Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit

October 9, 2024 5:35 PM

Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced its participation in the 2024 Maxim Healthcare Virtual Summit, scheduled to take place from October 15 to 17, 2024. Ilan Hadar, Chief Executive Officer and Dr. Mitchell Shirvan, Chief Scientific and Development Officer will join a fireside chat hosted by Jason...

Read more